RBC lifts Pacira stock price target to $26 following litigation settlement

On Tuesday, RBC Capital Markets updated their financial outlook for Pacira Pharmaceuticals (NASDAQ:PCRX), increasing the price target to $26.00 from the previous $22.00. The stock, currently trading at $27.41, has shown remarkable strength with a 46.3% gain over the past six months. According to InvestingPro data, analysts' price targets for the stock range from $21 to $48. The adjustment comes in the wake of Pacira's announcement on Monday that it has reached a settlement regarding the litigation over its flagship product, Exparel. Despite the broader market's macroeconomic uncertainties, RBC Capital has decided to maintain a Sector Perform rating on the company's shares.

The settlement of the Exparel litigation marks the end of more than a year of legal disputes, which had cast a shadow of uncertainty over Pacira's stock. Analysts at RBC Capital view the resolution as a positive outcome for the company, ensuring five years of market exclusivity for Exparel. This positive development aligns with InvestingPro analysis, which shows the company maintaining a GREAT financial health score of 3.12, with expectations of net income growth this year. This period is seen as crucial for Pacira to capitalize on internal growth drivers, such as Group Purchasing Organization (GPO) contracting and the NOPAIN Act, which could enhance the drug's use across various surgical segments.

The agreement also allows Pacira to concentrate on achieving its "5x30" objectives, which are expected to drive long-term revenue growth through pipeline development extending into the 2030s. Following discussions with management, RBC Capital reports that the company remains confident in Exparel's competitive position, even considering the terms of the recent settlement.

The positive developments for Pacira come at a time when the healthcare sector is navigating through a phase of macroeconomic uncertainty. Despite these challenges, RBC Capital's updated price target reflects a reassessment of the company's valuation in light of the litigation settlement and its implications for Pacira's future performance. InvestingPro analysis suggests the stock is currently undervalued, with revenue expected to grow by 7% in the coming year. For deeper insights into Pacira's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Pacira BioSciences has announced a settlement in its patent litigation concerning its product, EXPAREL, with Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, and eVenus Pharmaceuticals Laboratories. This agreement will allow Fresenius to sell limited volumes of a generic version starting in 2030, with no volume restrictions beginning in 2039. Analysts from H.C. Wainwright have responded positively by raising their price target for Pacira to $65, maintaining a Buy rating, while Raymond (NSE:RYMD) James continues to rate the stock as Market Perform. The settlement is considered a strategic win for Pacira, providing clarity on the exclusivity period for EXPAREL, which is central to the company's revenue. Additionally, Pacira has initiated a Phase 2 study for its gene therapy candidate, PCRX-201, aimed at treating osteoarthritis of the knee. This trial, part of Pacira's '5x30' strategy, seeks to evaluate the safety and efficacy of the therapy, with initial results expected by the end of 2026. The therapy has already shown promising results in a previous Phase 1 study, indicating extended pain relief and a favorable safety profile. Pacira's ongoing developments reflect its commitment to advancing non-opioid pain management therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.